Bevacizumab biosimilar - Alphamab/R-PharmAlternative Names: Avastin biosimilar - Alphamab/R-Pharm; RPH 001
Latest Information Update: 15 May 2015
At a glance
- Originator Alphamab; R-Pharm
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer
- Phase I Cancer